Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iSAP-0913
- Development stage
- Unknown
- Lead developer
- Isap Biotechnology
- Modality
- Peptides
01
Overview
iSAP-0913: sourced facts only. name: "iSAP-0913 binds HER2 receptor to form nano-assemblies on tumor cells, contributed by the design of self-assembling peptide sequence in linker." [DOI:10.1158/1538-7445.am2025-5646]; target: "iSAP-0913 binds HER2 receptor to form nano-assemblies on tumor cells, contributed by the design of self-assembling peptide sequence in linker." [DOI:10.1158/1538-7445.am2025-5646]; developer: "Isap (Beijing) Biotechnology Co., Ltd., Beijing, China." [DOI:10.1158/1538-7445.am2025-5646]; modality: "Herein, we report preclinical studies of iSAP-0913, a novel in vivo self-assembled peptide-drug conjugate (PDC) targeting HER2." [DOI:10.1158/1538-7445.am2025-5646]
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on iSAP-0913.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iSAP-0913.